February 20, 2026
Clinical Updates
Keytruda® (pembrolizumab), Keytruda Qlex™ (pembrolizumab/berahyaluronidase alfa-pmph) – New indication
February 11, 2026 - Merck announced the FDA approval of Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab/ berahyaluronidase alfa-pmph), in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimen.
Drug Safety
Hormone replacement therapy – FDA approves removal of boxed warnings
February 12, 2026 - The FDA approved labeling updates for six hormone replacement therapy (HRT) products, removing the statements related to cardiovascular disease, breast cancer and probable dementia from the boxed warning.
New Generics
Teflaro® (ceftaroline fosamil) – First-time generic
February 16, 2026 - Apotex launched an AB-rated generic version of AbbVie’s Teflaro (ceftaroline fosamil) intravenous injection.